Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | RXRB | P28702 | 3/20 | 0.57 |
| ▸ | RXRA | P19793 | 2/20 | 0.57 |
| ▸ | RXRG | P48443 | 2/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.50 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31506355 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL29966888 | 0.96 | ALDH1A1 (0.92) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL1713977 | 0.96 | ALDH1A1 (0.92) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL23090398 | 0.94 | ALDH1A1 (0.88) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL15927492 | 0.94 | ALDH1A1 (0.88) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL9477896 | 0.91 | ALDH1A1 (0.83) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| Hydrochloric Acid SCHEMBL10587733 | 0.89 | ALDH1A1 (0.80) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL14124788 | 0.88 | ALDH1A1 (0.79) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL14524760 | 0.85 | ALDH1A1 (0.72) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL14124796 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MAPTKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | claimed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | claimed |
| EP-0382411-B1 | Delivery of cytotoxic agents | LILLY CO ELI (US) | 1994-12-07 | — | — | EP | claimed |
| WO-1994001137-A1 | METHOD FOR DELIVERY OF CYTOTOXIC AGENTS AND COMPONENTS THEREOF | HYBRITECH INCORPORATED (US) | 1994-01-20 | — | — | WO | claimed |
| EP-0382411-A2 | Delivery of cytotoxic agents | ELI LILLY AND COMPANY (US) | 1990-08-16 | — | — | EP | claimed |
| US-12630556-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | DART NEUROSCIENCE LLC (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250092047-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| US-20240366608-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | LUPIN LIMITED (IN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024196236-A1 | NOVEL COMPOUND AS ENDOTHELIAL TO MESENCHYMAL TRANSITION (ENDMT) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-09-26 | — | — | WO | disclosed |
| WO-1996015099-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-05-23 | — | — | WO | disclosed |
| EP-0382411-B1 | Delivery of cytotoxic agents | LILLY CO ELI (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994001137-A1 | METHOD FOR DELIVERY OF CYTOTOXIC AGENTS AND COMPONENTS THEREOF | HYBRITECH INCORPORATED (US) | 1994-01-20 | — | — | WO | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0382411-A2 | Delivery of cytotoxic agents | ELI LILLY AND COMPANY (US) | 1990-08-16 | — | — | EP | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0072905-A1 | Bis-oxadiazolyl-naphthalenes, process for their preparation and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366608-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | NRAS, KRAS, PRMT1 | ALDH1A1 2604/4885MAPT 1630/4885KDM4E 514/4885 |
| US-20250092047-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | ALDH1A1 1494/4885MAPT 920/4885KDM4E 3050/4885 |
| US-12630556-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | PDE1A, PDE12, PDE1B | ALDH1A1 1599/4885MAPT 375/4885KDM4E 1923/4885 |
| US-12435066-B2 | Substituted tricyclic compounds | SOS1, RSU1, KSR1 | ALDH1A1 3879/4885MAPT 150/4885KDM4E 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.